sales@jinjingroup.com

  News Introduction

Vinpocetine(CAS 42971-09-5) improves neurological deficits in patients

Date : 2016/9/27 10:02:06

Recently, Xinfeng County, Guangdong Province, Chinese medicine hospital researchers published papers to study the monosialoglycans ganglioside combined with vinpocetine(CAS 42971-09-5) in patients with cerebral infarction in the application. Studies have shown that monosialoglycans ganglioside combined with vinpocetine treatment of acute cerebral infarction patients with effective, significantly improved neurological deficits in patients and improve their quality of life. The article published in the 07th issue of 2015, "Clinical Medicine" magazine.

Forty-six patients with acute cerebral infarction treated by the Department of Neurology, Xinfeng Hospital of Traditional Chinese Medicine were randomly divided into study group and control group (n = 43). The control group was treated with vinpocetine(CAS 42971-09-5) (40 mg, intravenous infusion, 1 time / d); the treatment group were given monosialoglycans ganglioside (40 mg, 1 time / d) on the basis of the control group; (NIHSS score) and ADL score (ADL score) were compared between the two groups in terms of clinical efficacy, neurologic deficit score (NIHSS score) and daily activity score (ADL score).

The total effective rate of observation group was significantly higher than the control group, the difference was statistically significant (P <0.05); observation group NIHSS score and ADL score were significantly lower than the control group, the difference was statistically significant (P <0.01).